Literature DB >> 27097363

NUP98 fusion oncoproteins interact with the APC/C(Cdc20) as a pseudosubstrate and prevent mitotic checkpoint complex binding.

Valentina Salsi1, Sebastian Fantini1, Vincenzo Zappavigna1.   

Abstract

NUP98 is a recurrent partner gene in translocations causing acute myeloid leukemias and myelodisplastic syndrome. The expression of NUP98 fusion oncoproteins has been shown to induce mitotic spindle defects and chromosome missegregation, which correlate with the capability of NUP98 fusions to cause mitotic checkpoint attenuation. We show that NUP98 oncoproteins physically interact with the APC/C(Cdc20) in the absence of the NUP98 partner protein RAE1, and prevent the binding of the mitotic checkpoint complex to the APC/C(Cdc20). NUP98 oncoproteins require the GLEBS-like domain present in their NUP98 moiety to bind the APC/C(Cdc20). We found that NUP98 wild-type is a substrate of APC/C(Cdc20) prior to mitotic entry, and that its binding to APC/C(Cdc20) is controlled via phosphorylation of a PEST sequence located within its C-terminal portion. We identify S606, within the PEST sequence, as a key target site, whose phosphorylation modulates the capability of NUP98 to interact with APC/C(Cdc20). We finally provide evidence for an involvement of the peptidyl-prolyl isomerase PIN1 in modulating the possible conformational changes within NUP98 that lead to its dissociation from the APC/C(Cdc20) during mitosis. Our results provide novel insight into the mechanisms underlying the aberrant capability of NUP98 oncoproteins to interact with APC/C(Cdc20) and to interfere with its function.

Entities:  

Keywords:  NUP98; acute myeloid leukemia; anaphase promoting complex; cell cycle; mitotic checkpoint; myelodisplastic syndrome; nucleoporins; oncogenes

Mesh:

Substances:

Year:  2016        PMID: 27097363      PMCID: PMC5004700          DOI: 10.1080/15384101.2016.1172156

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  34 in total

1.  The mitotic checkpoint protein hBUB3 and the mRNA export factor hRAE1 interact with GLE2p-binding sequence (GLEBS)-containing proteins.

Authors:  X Wang; J R Babu; J M Harden; S A Jablonski; M H Gazi; W L Lingle; P C de Groen; T J Yen; J M van Deursen
Journal:  J Biol Chem       Date:  2001-05-14       Impact factor: 5.157

Review 2.  Nucleoporin Nup98: a gatekeeper in the eukaryotic kingdoms.

Authors:  Masaaki Iwamoto; Haruhiko Asakawa; Yasushi Hiraoka; Tokuko Haraguchi
Journal:  Genes Cells       Date:  2010-06-07       Impact factor: 1.891

Review 3.  The Molecular Biology of Spindle Assembly Checkpoint Signaling Dynamics.

Authors:  Andrea Musacchio
Journal:  Curr Biol       Date:  2015-10-19       Impact factor: 10.834

4.  Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis.

Authors:  H Zou; T J McGarry; T Bernal; M W Kirschner
Journal:  Science       Date:  1999-07-16       Impact factor: 47.728

5.  Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells.

Authors:  Jeong-Min Kim; Ho-Yong Sohn; Sun Young Yoon; Jung-Hwa Oh; Jin Ok Yang; Joo Heon Kim; Kyu Sang Song; Seung-Moo Rho; Hyang-Sook Yoo; Hyan Sook Yoo; Yong Sung Kim; Jong-Guk Kim; Nam-Soon Kim
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

6.  The vertebrate GLFG nucleoporin, Nup98, is an essential component of multiple RNA export pathways.

Authors:  M A Powers; D J Forbes; J E Dahlberg; E Lund
Journal:  J Cell Biol       Date:  1997-01-27       Impact factor: 10.539

7.  NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia.

Authors:  S Z Raza-Egilmez; S N Jani-Sait; M Grossi; M J Higgins; T B Shows; P D Aplan
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

8.  Identification and characterization of nuclear pore subcomplexes in mitotic extract of human somatic cells.

Authors:  Y Matsuoka; M Takagi; T Ban; M Miyazaki; T Yamamoto; Y Kondo; Y Yoneda
Journal:  Biochem Biophys Res Commun       Date:  1999-01-19       Impact factor: 3.575

9.  RAE1 is a shuttling mRNA export factor that binds to a GLEBS-like NUP98 motif at the nuclear pore complex through multiple domains.

Authors:  C E Pritchard; M Fornerod; L H Kasper; J M van Deursen
Journal:  J Cell Biol       Date:  1999-04-19       Impact factor: 10.539

10.  Phosphorylation-dependent degradation of MEF2C contributes to regulate G2/M transition.

Authors:  Sara Badodi; Fiorenza Baruffaldi; Massimo Ganassi; Renata Battini; Susanna Molinari
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

View more
  5 in total

Review 1.  Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies.

Authors:  Nicole L Michmerhuizen; Jeffery M Klco; Charles G Mullighan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

2.  The miR-196b miRNA inhibits the GATA6 intestinal transcription factor and is upregulated in colon cancer patients.

Authors:  Sebastian Fantini; Valentina Salsi; Luca Reggiani; Antonino Maiorana; Vincenzo Zappavigna
Journal:  Oncotarget       Date:  2017-01-17

Review 3.  The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?

Authors:  Andrea Ghelli Luserna di Rorà; Giovanni Martinelli; Giorgia Simonetti
Journal:  J Hematol Oncol       Date:  2019-11-26       Impact factor: 17.388

Review 4.  CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies.

Authors:  Samantha Bruno; Andrea Ghelli Luserna di Rorà; Roberta Napolitano; Simona Soverini; Giovanni Martinelli; Giorgia Simonetti
Journal:  J Exp Clin Cancer Res       Date:  2022-04-30

Review 5.  The role of Anaphase Promoting Complex activation, inhibition and substrates in cancer development and progression.

Authors:  Cordell VanGenderen; Troy Anthony Alan Harkness; Terra Gayle Arnason
Journal:  Aging (Albany NY)       Date:  2020-08-15       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.